Skip to main content
Top
Published in: Journal of Neuro-Oncology 2/2015

01-06-2015 | Clinical Study

MRI findings and pathological features in early-stage glioblastoma

Authors: Makoto Ideguchi, Koji Kajiwara, Hisaharu Goto, Kazutaka Sugimoto, Sadahiro Nomura, Eiji Ikeda, Michiyasu Suzuki

Published in: Journal of Neuro-Oncology | Issue 2/2015

Login to get access

Abstract

Magnetic resonance imaging (MRI) is an important diagnostic tool for glioblastoma, with almost all cases showing characteristic imaging findings such as a heterogeneous-ring enhanced pattern associated with significant edema. However, MRI findings for early-stage glioblastoma are less clear. In this study, a retrospective review of MRI findings in five patients showed slight T2WI signal changes on initial scans that developed into typical imaging findings of a ring-like or heterogeneously enhanced bulky tumor within 6 months. The diagnoses based on initial MRI were low grade glioma in three cases, venous thrombosis in one case, and uncertain in one case. Four cases were treated with gross total resection, while one case underwent biopsy. Immunohistochemical examinations showed that two cases were p53-positive, and that all cases were IDH1 R132H-negative and had overexpression of EGFR. FISH analysis showed that all cases were 1p19q LOH-negative. De novo glioblastoma was the final diagnosis in all cases. Our results show that initial MRI findings in early-stage glioblastoma of small ill-defined T2WI hyperintense lesions with poor contrast develop to bulky mass lesions with typical findings for glioblastoma in as short a period as 2.5 months. The early MRI findings are difficult to distinguish from those for non-neoplastic conditions, including ischemic, degenerative or demyelinating processes. Thus, there is a need for proactive diagnosis of glioblastoma using short-interval MRI scans over several weeks, other imaging modalities, and biopsy or resection, particularly given the extremely poor prognosis of this disease.
Literature
1.
go back to reference Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF (1998) The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 49:436–440CrossRefPubMed Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF (1998) The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 49:436–440CrossRefPubMed
2.
go back to reference Oyama H, Ando Y, Aoki S, Kito A, Maki H, Hattori K, Tanahashi K (2010) Glioblastoma detected at the initial stage in its developmental process case report. Neurol Med Chir (Tokyo) 50:414–417CrossRef Oyama H, Ando Y, Aoki S, Kito A, Maki H, Hattori K, Tanahashi K (2010) Glioblastoma detected at the initial stage in its developmental process case report. Neurol Med Chir (Tokyo) 50:414–417CrossRef
3.
go back to reference Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE (1996) Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 27:65–73CrossRefPubMed Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE (1996) Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 27:65–73CrossRefPubMed
4.
go back to reference Utsuki S, Oka H, Miyajima Y, Kijima C, Yasui Y, Fujii K (2012) Glioblastoma without remarkable contrast enhancement on magnetic resonance imaging. ICJM 3:439–445. doi:10.4236/ijcm.2012.36082 Utsuki S, Oka H, Miyajima Y, Kijima C, Yasui Y, Fujii K (2012) Glioblastoma without remarkable contrast enhancement on magnetic resonance imaging. ICJM 3:439–445. doi:10.​4236/​ijcm.​2012.​36082
6.
go back to reference Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lutolf UM, Kleihues P (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64:6892–6899. doi:10.1158/0008-5472.CAN-04-1337 CrossRefPubMed Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lutolf UM, Kleihues P (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64:6892–6899. doi:10.​1158/​0008-5472.​CAN-04-1337 CrossRefPubMed
7.
go back to reference Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, Kleihues P, Ohgaki H (2000) Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 80:65–72CrossRefPubMed Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, Kleihues P, Ohgaki H (2000) Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 80:65–72CrossRefPubMed
8.
go back to reference Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H (2000) Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol 59:539–543PubMed Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H (2000) Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol 59:539–543PubMed
11.
go back to reference Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773CrossRefPubMedCentralPubMed Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773CrossRefPubMedCentralPubMed
12.
go back to reference Louis DN, Ohgaki H, Weistler OD, Cavenee WK (2007) WHO Classification of Tumours of the Central Nervous System. 4th edn. IARC Press, Lyon Louis DN, Ohgaki H, Weistler OD, Cavenee WK (2007) WHO Classification of Tumours of the Central Nervous System. 4th edn. IARC Press, Lyon
13.
go back to reference Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851–3857PubMed Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851–3857PubMed
14.
go back to reference Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, Miller DC (1998) Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 8:655–667CrossRefPubMed Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, Miller DC (1998) Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 8:655–667CrossRefPubMed
15.
go back to reference Chang KW, Sarraj S, Lin SC, Tsai PI, Solt D (2000) P53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis. Carcinogenesis 21:1441–1451CrossRefPubMed Chang KW, Sarraj S, Lin SC, Tsai PI, Solt D (2000) P53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis. Carcinogenesis 21:1441–1451CrossRefPubMed
16.
go back to reference Kramar F, Zemanova Z, Michalova K, Babicka L, Ransdorfova S, Hrabal P, Kozler P (2007) Cytogenetic analyses in 81 patients with brain gliomas: correlation with clinical outcome and morphological data. J Neurooncol 84:201–211. doi:10.1007/s11060-007-9358-7 CrossRefPubMed Kramar F, Zemanova Z, Michalova K, Babicka L, Ransdorfova S, Hrabal P, Kozler P (2007) Cytogenetic analyses in 81 patients with brain gliomas: correlation with clinical outcome and morphological data. J Neurooncol 84:201–211. doi:10.​1007/​s11060-007-9358-7 CrossRefPubMed
17.
go back to reference Wharton SB, Maltby E, Jellinek DA, Levy D, Atkey N, Hibberd S, Crimmins D, Stoeber K, Williams GH (2007) Subtypes of oligodendroglioma defined by 1p,19q deletions, differ in the proportion of apoptotic cells but not in replication-licensed non-proliferating cells. Acta Neuropathol 113:119–127. doi:10.1007/s00401-006-0177-2 CrossRefPubMedCentralPubMed Wharton SB, Maltby E, Jellinek DA, Levy D, Atkey N, Hibberd S, Crimmins D, Stoeber K, Williams GH (2007) Subtypes of oligodendroglioma defined by 1p,19q deletions, differ in the proportion of apoptotic cells but not in replication-licensed non-proliferating cells. Acta Neuropathol 113:119–127. doi:10.​1007/​s00401-006-0177-2 CrossRefPubMedCentralPubMed
21.
go back to reference Landy HJ, Lee TT, Potter P, Feun L, Markoe A (2000) Early MRI findings in high grade glioma. J Neurooncol 47:65–72CrossRefPubMed Landy HJ, Lee TT, Potter P, Feun L, Markoe A (2000) Early MRI findings in high grade glioma. J Neurooncol 47:65–72CrossRefPubMed
22.
go back to reference Ono K, Tohma Y, Yoshida M, Takamori M (2000) A case of glioblastoma multiforme which indicated the early stage on brain MRI. No To Shinkei 52:325–329 Ono K, Tohma Y, Yoshida M, Takamori M (2000) A case of glioblastoma multiforme which indicated the early stage on brain MRI. No To Shinkei 52:325–329
23.
24.
go back to reference Yetkin Z, Haughton VM (1995) Atypical demyelinating lesions in patients with multiple sclerosis. Neuroradiology 37:284–286CrossRefPubMed Yetkin Z, Haughton VM (1995) Atypical demyelinating lesions in patients with multiple sclerosis. Neuroradiology 37:284–286CrossRefPubMed
25.
go back to reference Osborn AG (1994) Astrocytomas and other glial neoplasms. In: Patterson AS (ed) Diagnostic Neuroradiology. A Text/Atlas Mosby, St. Louis, pp 529–578 Osborn AG (1994) Astrocytomas and other glial neoplasms. In: Patterson AS (ed) Diagnostic Neuroradiology. A Text/Atlas Mosby, St. Louis, pp 529–578
26.
go back to reference Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA (2002) How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 59:947–949CrossRefPubMed Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA (2002) How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 59:947–949CrossRefPubMed
31.
go back to reference Pirotte BJ, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O, Bruneau M, Rorive S, David P, Brotchi J (2009) Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery 64:471–481. doi:10.1227/01.NEU.0000338949.94496.85 (Discussion: 481)CrossRefPubMed Pirotte BJ, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O, Bruneau M, Rorive S, David P, Brotchi J (2009) Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery 64:471–481. doi:10.​1227/​01.​NEU.​0000338949.​94496.​85 (Discussion: 481)CrossRefPubMed
32.
go back to reference Bader JB, Samnick S, Moringlane JR, Feiden W, Schaefer A, Kremp S, Kirsch CM (1999) Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. Eur J Nucl Med 26:144–151CrossRefPubMed Bader JB, Samnick S, Moringlane JR, Feiden W, Schaefer A, Kremp S, Kirsch CM (1999) Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy. Eur J Nucl Med 26:144–151CrossRefPubMed
33.
go back to reference Torii K, Tsuyuguchi N, Kawabe J, Sunada I, Hara M, Shiomi S (2005) Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med 19:677–683CrossRefPubMed Torii K, Tsuyuguchi N, Kawabe J, Sunada I, Hara M, Shiomi S (2005) Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med 19:677–683CrossRefPubMed
34.
go back to reference Gumprecht H, Grosu AL, Souvatsoglou M, Dzewas B, Weber WA, Lumenta CB (2007) 11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas. Zentralbl Neurochir 68:19–23. doi:10.1055/s-2007-970601 CrossRefPubMed Gumprecht H, Grosu AL, Souvatsoglou M, Dzewas B, Weber WA, Lumenta CB (2007) 11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas. Zentralbl Neurochir 68:19–23. doi:10.​1055/​s-2007-970601 CrossRefPubMed
35.
go back to reference Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med 352: 987–996 doi:10.1056/NEJMoa043330 Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med 352: 987–996 doi:10.​1056/​NEJMoa043330
36.
go back to reference Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479–489PubMed Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479–489PubMed
Metadata
Title
MRI findings and pathological features in early-stage glioblastoma
Authors
Makoto Ideguchi
Koji Kajiwara
Hisaharu Goto
Kazutaka Sugimoto
Sadahiro Nomura
Eiji Ikeda
Michiyasu Suzuki
Publication date
01-06-2015
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2015
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-015-1797-y

Other articles of this Issue 2/2015

Journal of Neuro-Oncology 2/2015 Go to the issue